Replies to post #112316 on Biotech Values

[dia76ca]

Quote:
__________________________________________________________________
"Insofar as there are no hard data showing that Bavituximab has efficacy against HCV..."
__________________________________________________________________

The PPHM press release says,"In prior HCV clinical trials, bavituximab administered as monotherapy in single and multiple doses demonstrated a positive safety profile with no dose-limiting toxicities or serious adverse events. Bavituximab as a monotherapy also showed promising on therapy antiviral activity of up to 1.5 log viral load reduction."
They reported these results some time ago. What you said seems to dismiss this "hard data".

Regards, Dia

[DewDiligence]

No discussion of the HCV arena would be complete without Bavituximab, so here is PPHM’s latest PR:

http://finance.yahoo.com/news/Peregrine-Presents-Phase-Ib-iw-304801467.html?x=0&.v=1

(The above is facetious, of course.)